Tue, Sep 23, 2014, 6:29 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Optimer Pharmaceuticals, Inc. (OPTR) Message Board

  • loriskhireward loriskhireward Nov 16, 2011 10:04 AM Flag

    Gotta like this comment from Zack's...

    just a tidbit from today's comments:

    However, we are concerned about Vancocin (approved for the treatment of clostridium difficile infection), which faces competition from Optimer Pharmaceuticals Inc.’s (NasdaqGM:OPTR - News) Dificid (fidaxomicin), which is marketed in the US. The candidate is currently under review in the EU. We believe that Dificid could turn out to be a major threat to Vancocin, which is currently not protected by any patent.

    I guess "doc" knows more...

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Lo! wasssup bu!

      what would have been more concerning is dificid with da same price as vanco... pedro may just have gone a little gone overboard with da pricing... but das good, it's all good!...
      these drugs are a lot cheaper than sayyy... provenge whose benefit is to extend 4 months of life... these two drugs actually saves life... provenge costs $93,000 to a mere $2,800 for dificid and $1,500 for vanco!... yikes! wasssup wid dat?

      on second thought pedro should have gone gusto with pricing!!!...

      aloha bu!

      • 1 Reply to funindasun_1
      • lol...I just don't like a "doc" telling me he's going to use a less effective drug just because it's been his "tried & true" treatment. when a new, more effective drug comes out, i expect the drug to gain acceptance, and not resistance 2nd to cost BEFORE considering the heavy expense burden placed on payers (govt type & pvt insur) and hospitals who are having to explain this dinosaur-like behavior. imo, of course - aloha, and keep the tip up!

12.780.00(0.00%)Oct 23 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.